Compare Adaptive Biotechnologies Corp (ADPT) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs VanEck Australian Floating Rate ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while VanEck Australian Floating Rate ETF trades at $50.97. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | FLOT | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $51.09 |
52-Week Low | $10.24 | $50.72 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FLOT trades at $50.96, up 0.08% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF focuses on high-quality floating rate bonds, offering a 4.0% SEC yield, and recent dividends include $0.18 paid in June 2026. News highlights potential Fed rate hikes as a catalyst for yield growth, while credit quality remains strong with minimal default risk.
Outlook is cautious due to bearish technicals and interest rate uncertainty, but FLOT provides a stable income stream with low credit risk. Key risks include inflation-driven rate volatility and economic shifts affecting bond yields, making it suitable for investors seeking short-term cash parking with modest returns above Treasuries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
